Rubicon Research

Rubicon Research (Rubicon Research Pvt. Ltd.) is an IP led, specialty pharmaceutical company focused on its mission to provide innovative yet affordable patient-centered products and solutions so as to address unmet needs around the world. The company leverages its proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, topical, drug device combinations and fixed-dose combinations.

Rubicon Research Pvt. Ltd.
Private Limited company
IndustryPharmaceutical
FoundedMumbai, India 1999
Headquarters
Mumbai, India
,
India
ProductsPharmaceuticals
Number of employees
200 (2010)
Websitewww.rubicon.co.in

Rubicon Research operates out of four locations—the corporate HQ and R&D center in Thane, India, the R&D center in Concord, Canada, the manufacturing site in Ambernath, India, and the business development, marketing, sales and regulatory office in Plainsboro, US.

History and evolution

Rubicon Research was founded in 1999 by Pratibha Pilgaonkar, Sudhir Pilgaonkar, and Maharukh Rustomjee. It started operations in 2000 as India’s first independent product development company, establishing itself as a well-recognized outsourcing partner to the global healthcare and pharmaceutical industry.

In 2009 the company commissioned an oral solids manufacturing facility in Ambernath, India. The 140,000+ square feet state-of-the-art manufacturing plant is compliant with US FDA and EU specifications.

Rubicon Research also developed some novel functional excipients and in 2012, Avantor Performance Materials signed an agreement with the company to develop and market a novel gastro-retentive excipient that enables the delivery of molecules with a window of absorption.[1]

Looking to enter regulated markets, Rubicon Research filed its first ANDA in 2010, and received its first own ANDA approval in 2014.

The company expanded into the US market in 2014 and established Advagen Pharma. In 2016, the company scaled up its 100th product and has gone on to expand its development expertise with a commercial focus, leading to multiple product approvals and launches.

In 2016, in Series B funding, the private equity firm Everstone Group bought out the stakes of Kotak Private Equity and Maharukh Rustomjee. [2] The company underwent a transformation and became an IP-led differentiated generics pharmaceutical company with a strong focus on the US market.

In 2019, Rubicon Research received a USD 100 million growth capital commitment from General Atlantic and acquired 15 ANDAs to augment its generic portfolio. [3][4] In line with its goal to establish a global development network, Rubicon Research acquired Impopharma Canada Ltd in late 2019, and established Rubicon Research Canada Ltd. [5] The Canadian development facility specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, and dermal products.

In May 2020, in the wake of the COVID-19 pandemic, Rubicon Research committed Rs 2 crore for the fight against COVID-19. This included a donation of Rs 1.9 crore worth of Hydroxychloroquine (1.5 million tablets) to the Government of Maharashtra to help frontline workers and high-risk patients.

Recent news

December 2019: Rubicon Research acquired Impopharma Canada Ltd and established Rubicon Research Canada Ltd.

May 2020: Rubicon Research received US FDA approval for its ANDA for Amantadine Capsules USP, 100 mg.

Rubicon Research received US FDA approval for its ANDA for Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg.

References
  1. "Avantor, Rubicon Research Collaborate on Functional Excipient Development". Drug Discovery and Development. 16 October 2012.
  2. "Everstone buys Mumbai-based drug tech firm Rubicon for Rs 220-crore - The Economic Times". The Economic Times.
  3. "General Atlantic acquires significant shareholding in Rubicon Research". The Financial Express. 9 April 2019.
  4. "Everstone scores one of its best exits as General Atlantic strikes a control deal". VCCircle. 1 April 2019.
  5. "Rubicon Research Acquires Impopharma Canada". Financial Post.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.